Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Neuroimmunology

• Publication date

  2011-12-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jneuroim.2011.09.010PMID 22035961
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of leukocyte function by adenosine receptors.

  2011cited by this paper
• A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

  2010cited by this paper
• The cladribine conundrum: deciphering the drug's mechanism of action

  2010cited by this paper
• Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis

  2009cited by this paper
• Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.

  2008cited by this paper
• Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders.

  2006cited by this paper
• Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).

  2005cited by this paper
• Determination of the deoxycytidine kinase activity in cell homogenates with a non-radiochemical assay using reversed-phase high performance liquid chromatography; Identification of a novel metabolite of 2-chlorodeoxyadenosine.

  2004cited by this paper
• The antileukemia drug 2-chloro-2'-deoxyadenosine: an intrinsic transcriptional antagonist.

  2004cited by this paper
• Hairy-cell leukaemia as a model for drug development.

  2003cited by this paper
• Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.

  2001cited by this paper
• Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria.

  2001cited by this paper
• Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.

  2000cited by this paper
• Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells.

  1998cited by this paper
• A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis.

  1998cited by this paper
• Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants.

  1997cited by this paper
• 2-Chloro-2-deoxyadenosine--a novel immunosuppressive agent.

  1993cited by this paper
• Cladribine (2-chloro-deoxyadenosine, CDA): an inhibitor of human B and T cell activation in vitro.

  1993cited by this paper
• Cladribine (2-chlorodeoxyadenosine)

  1992cited by this paper
• Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.

  1985cited by this paper
• Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

  1983cited by this paper
• Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.

  1983cited by this paper
• Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.

  1980cited by this paper

• A drug evaluation narrative review of cladribine as a treatment for multiple sclerosis.

  2025cites this paper
• Cladribine Ameliorates Imiquimod Induced Murine Psoriasiform Dermatitis

  2025cites this paper
• Treg Susceptibility to Cladribine-Induced Depletion Correlates With Therapy Response in Patients With Multiple Sclerosis

  2025cites this paper
• Cladribine Preserves Normal Central Nervous System Cellular Activity and Promotes Neuroprotection to Oxidative Stress Damage

  2025cites this paper
• Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study)

  2023cites this paper
• The Development of the Combination Drug Leukovir® Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.

  2023cites this paper
• Prolonged observation after the use of cladribine in multiple sclerosis: efficacy and safety

  2023cites this paper
• Molecular signature associated with cladribine treatment in patients with multiple sclerosis

  2023cites this paper
• Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4

  2022cites this paper
• Cladribine Reduces Trans-Endothelial Migration of Memory T Cells across an In Vitro Blood–Brain Barrier

  2022cites this paper
• Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation

  2022cites this paper
• Pharmacokinetic Study and Toxicity of Leukovir: A New Combined Drug for the Treatment of Multiple Sclerosis

  2022cites this paper
• Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis

  2021cites this paper
• Immunomodulatory Effects Associated with Cladribine Treatment

  2021cites this paper
• Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint

  2021cites this paper
• MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine

  2021cites this paper
• A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment

  2020cites this paper
• Cladribine modifies functional properties of microglia

  2020cites this paper
• COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment

  2020cites this paper
• Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient

  2020cites this paper
• Long‐term peripheral immune cell profiling reveals further targets of oral cladribine in MS

  2020cites this paper
• Immunotropic Activity of a New Cladribin/Ribavirin-Based Composition

  2020cites this paper
• Immune reconstitution therapies: concepts for durable remission in multiple sclerosis

  2019cites this paper
• General Principles of Immunotherapy in Neurological Diseases

  2019cites this paper
• Mécanismes d’actions des biothérapies dans la SEP

  2019cites this paper
• Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells

  2018cites this paper
• Cladribine Tablets: A Review in Relapsing MS

  2018cites this paper
• Cladribine: mechanisms and mysteries in multiple sclerosis

  2018cites this paper
• The cost and burden of schizophrenia in Portugal in 2015

  2018cites this paper
• An update on cladribine for relapsing-remitting multiple sclerosis

  2017cites this paper
• Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)

  2017cites this paper
• Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells

  2015cites this paper
• Expression of p53 protein and the histomorphological view of epidermis in experimental animals after cladribine application

  2014cites this paper
• Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.

  2014cites this paper
• Intrinsic Apoptosis Pathway in Fallopian Tube Epithelial Cells Induced by Cladribine

  2014cites this paper
• Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis

  2013cites this paper